三阴性转移性乳腺癌免疫治疗的研究进展
摘要
关键词
全文:
PDF参考
[1]尹方旭,杨振林,王松,张湘生,王晓红.程序性死亡受体1/程序性死亡受体配体1免疫检查点抑制剂 在乳腺癌免疫治疗中的应用前景[J].癌症进展.2022,20(04):325-332.
[2]Yin L,Duan JJ,Bian XW,et al.Triple-negative breast cancer molecular subtyping and treatment progress [J].Breast Cancer Res,2020,22(1):61.
[3]Zhu Y,Zhu X,Tang C,et al.Progress and challenges of immunotherapy in triple- negative breast cancer [J].Biochim Biophys Acta Rev Cancer,2021,1876(2):188593.
[4]Zeichner SB,Terawaki H,Gogineni K.A review of systemic treatment in metastatic triple-negative breast cancer [J].Breast Cancer Basic &ClinicalResearch,2016,10(10):25-36.
[5]Dunn GP, Old LJ,Schreiber RD.The three Es of cancer immunotherapy [J].Annu Rev Immunol,2004,22:329-600.
[6]DuPage M,Mazumdar C,Schmidt LM,et al.Expression of tumour-specific antigens underlies cancer immunoediting [J].Nature,2012,482(7385):405-409.
[7]Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy [J].Nature,2019,574(7780):696-701.
[8]Rooney MS,Shukla SA,Wu CJ,et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity [J].Cell,2015,160(1-2):48-61.
[9]龚畅,林群,宋尔卫.肿瘤免疫治疗机制及乳腺癌免疫治疗进展[J/OL].中华临床医师杂志(电子版),2020,14(11):857-861.
[10]何李华,朱秀之,江一舟.三阴性乳腺癌免疫治疗研究进展[J].中国临床药理学与治疗学.2023,28(08):842-853
[11]De Miguel M, Calvo E.Clinical challenges of immune checkpoint inhibitors.wCancer Cell,2020,38(3):326-333.
[12]Heeke AL,Tan AR.Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.Cancer Metastasis Rev,2021,40(2):537-547.
[13]Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy [J].Nat Rev Cancer,2012,12(4):252-264.
[14]Dogukan R,Uçak R,Dogukan FM,et al.Correlation between the expression of PD-L1 and clinicopathological parameters in triple negative breast cancer patients [J]. Eur J Breast Health,2019,15(4):235-241.
[15]Adams S,Loi S,Toppmeyer D, et al.Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B [J].Clin Oncol, 2017, 35(15 Suppl): 1088.
[16]Nanda R,Chow LQ,Dees EC,et al.Pembrolizumab in patients with advanced triple-negative breast cancer:phase Ib KEYNOTE-012 study [J].Clin Oncol,2016, 34(21):2460-2467.
[17]俞鑫,孙圣荣,王卫星.转移性乳腺癌免疫治疗研究现状[J].中国普外基础与临床杂志,2022,29(04):539-544.
(1 摘要 Views, 1 PDF Downloads)
Refbacks
- 当前没有refback。